INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
INSMED Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$95.29−0.98 (-1.02%)
Close on Oct 19, 2026
- Market cap
- $20.71B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$70.47 (−42.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
INSMED Inc grew revenue 185.8% to $1.14B over the twelve months to Jun 30, 2026. Free cash flow was -$807.67M.
Revenue
$1.14B
+185.8% vs. a year earlier
Operating income
-$840.62M
TTM Q2 2026
Free cash flow
-$807.67M
TTM Q2 2026
EPS, diluted
-$4.11
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $20.71B
- P/E ratio
- –
- Price to sales
- 18.21
- Price to book
- 27.34
- Dividend yield
- –
- Free cash flow yield
- -3.90%
Fundamentals
- Revenue
- $1.14B
- Net income
- -$875.31M
- EPS, diluted
- -$4.11
- Free cash flow
- -$807.67M
- Book value per share
- $3.49
- Diluted shares
- 217M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.14B+185.8% YoY
Gross profit
$949.42M+215.0% YoY
Operating income
-$840.62M
Net income
-$875.31M
EPS, diluted
-$4.11
Free cash flow
-$807.67M
Reported periodTrailing twelve months